Meet our CBO, Christine Ruckenbauer, in person on December 4 or online afterwards, December 4-5.
The RESI (Redefining Early Stage Investments) event in London is the perfect platform for early-stage biotech startups like RIANA Therapeutics to connect with potential investors, explore funding opportunities, and showcase our innovative approach to advancing cancer therapies.
We look forward to networking with industry leaders and discussing how RIANA’s STAT5 inhibitor program is paving the way for new treatments in oncology. If you’ll be there, we’d love to connect!
In a recent article for the Brutkasten magazine RIANA Therapeutics CEO Anna Orlova, Christopher Trummer (Celeris Therapeutics), and Peter Llewellyn-Davies (President Biotech-Austria) discuss the challenges and opportunities facing the biotech industry.
“It is always difficult to explain to people who are not familiar with the life science industry what our challenges are and why we are not yet making sales.” says Anna Orlova.
“Fact is, Biotech is not easy. But it is also a fact that we do something for the health of humanity and that we do it with passion. And the fact is that biotech is one of the most innovative industries in Austria and makes a significant contribution to achieving one of the highest research and development rates in the EU. Austria took third place in the EU, and the trend is rising.”, says Peter Llewellyn-Davies.
RIANA team had an incredible time running! The energy, teamwork, and camaraderie made it unforgettable. We were proud to send two teams of three this year, and the best part? We improved our results from 2023!
It was a perfect day to step away from the lab, have fun, and strengthen our bond as a team. We’re already planning our next sporty challenges, and I couldn’t be more excited. Huge thanks to everyone at RIANA for creating such a fantastic atmosphere – here’s to more shared adventures!
From left to right: Anna, Dominika, Anna, Tobias, Angela and Christine
We are delighted to announce that RIANAtx will be attending the BIO-EUROPE partnering conference, from November 4th to November 11th in the beauftiful city of Stockholm.
We look forward to presenting our recent data and connecting with leading business executives and early-stage investors in the life sciences and biotech community to foster new and exciting business opportunities!
Vienna, June 2024. We are pleased to announce the formation of our Scientific Advisory Board (SAB), which includes leading experts in the field of cancer research and small molecule development. This milestone marks a significant step forward in our mission to demonstrate how our platform screening approach for protein-protein interaction inhibitors and our pipeline molecules can improve the lives of cancer patients.
Anna Quattropani, PhD VP Chemisty Anavo Tx, Expert in medicinal chemistry
Anna brings over 20 years of experience in medicinal chemistry and drug discovery, with a strong track record of advancing clinical candidates through to Phase 2/3. She has invented small molecules for neurodegenerative diseases and reproductive health. Her expertise spans targeted protein degradation, enzyme inhibition, GPCR modulation, and protein-protein interactions across various therapeutic areas. Currently SVP of Chemistry and Non-Clinical Development at Anavo Therapeutics, Anna holds 48 patents in oral and CNS small molecule drug discovery, medicinal chemistry, and synthetic organic chemistry.
Jürgen Moll, PhD Ex-Boehringer Ingelheim, Expert in cancer drug development
Jürgen is a distinguished expert in cancer research and preclinical drug development, focusing on cancer cell targeting and immuno-oncology with small molecules, antibodies, and nanobodies. He has advanced oncology drugs at big pharma companies like Novartis, Pfizer, and Sanofi, as well as biotech spin-offs. Jürgen has held leadership roles at Sanofi, Boehringer-Ingelheim, and Nerviano Medical Sciences. An international consultant, SAB member, and lecturer, he holds a PhD in Biochemistry from the University of Basel and a degree in Microbiology from the University of Bayreuth.
Peter Nussbaumer, PhD KHAN/LDC, Expert in medicinal chemistry
Peter has over 30 years of industry experience in drug discovery. Before joining the LDC, he held key roles in medicinal chemistry at Sandoz and Novartis, most recently as Executive Director and Senior Unit Head of Chemistry at Novartis Institutes for Biomedical Research. He has managed numerous drug discovery projects and coordinated interdisciplinary and international teams. Peter has published extensively in peer-reviewed journals, is a co-inventor on several patents, and holds a PhD in organic chemistry from the University of Technology, Vienna.
Prof. Richard Moriggl, PhD Co-founder, Expert in STAT/JAK Biology
Prof. Moriggl is a leading expert in STAT biology, with significant contributions to understanding STAT3/5 signaling in normal and cancer cells. He was a Professor for Functional Cancer Genomics at Vetmeduni Vienna from 2014 to 2022 and has been a successful PI for 17 years, overseeing personnel, funding, and scientific management. As director of the Ludwig Boltzmann Institute for Cancer Research for 14 years, he shaped a successful research program and managed an annual budget of up to €2.5 million.
Congratulations to our brilliant scientist, Tobias Suske, on publishing his PhD study in the high-impact Journal of Clinical Investigation (JCI)!
In this paper, Tobias explored molecular mechanisms of how mutated hyperactive STAT5 causes T cell acute lymphoblastic leukemia (T-ALL). His work sheds light on the mechanisms underlying this disease and validates STAT5 as a key target in T-ALL and cancer.
We couldn’t be prouder to have him as part of our team, driving innovation and pushing scientific discovery’s boundaries.
We are delighted to announce that RIANAtx will be attending the LSX World Congress, from April 29th to April 30th in the vibrant city of London.
We look forward to presenting our recent data and connecting with early-stage investors in the life sciences and biotech community to foster new and exciting business opportunities!
We are delighted to announce that RIANAtx will be attending the BIO-EUROPE SPRING partnering conference, from March 18th to March 20th in the beauftiful city of Barcelona.
We look forward to presenting our recent data and connecting with leading business executives and early-stage investors in the life sciences and biotech community to foster new and exciting business opportunities!
In our endeavor to connect with leading business executives and early-stage investors in the life science and biotech community, it was a great pleasure to participate in the Inv€$tival Showcase and present our company in the “Startup Biotech” category.
We are delighted to announce that RIANAtx will be attending the BIO-EUROPE partnering conference, from November 6th to 8th in Munich, Germany.
We look forward to connecting with leading business executives and early-stage investors in the life sciences and biotech community to foster new and exciting business opportunities!
RIANA Therapeutics 